Provided by Tiger Fintech (Singapore) Pte. Ltd.

Candel Therapeutics, Inc.

8.75
+0.810010.20%
Post-market: 8.750.00000.00%19:59 EDT
Volume:1.02M
Turnover:8.70M
Market Cap:413.31M
PE:-5.03
High:8.79
Open:7.96
Low:7.96
Close:7.94
Loading ...

Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations

Benzinga
·
11 Dec 2024

Candel Therapeutics Shares More Than Triple in Value After Co's Prostate Cancer Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics Stock Surges Over 100% - Here's Why

Benzinga
·
11 Dec 2024

US Consumer Prices Rise in Line With Expectations in November as US Equity Futures Rise Pre-Bell

MT Newswires Live
·
11 Dec 2024

Candel Therapeutics Reports Mixed Trial Results for CAN-2409

TIPRANKS
·
11 Dec 2024

Candel Therapeutics Inc - Phase 2B Trial for Can-2409 Did Not Meet Primary Endpoint

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics Shares Soar Premarket on Prostate Cancer Study

Dow Jones
·
11 Dec 2024

Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump

MT Newswires Live
·
11 Dec 2024

Candel's cancer therapy meets late-stage trial goal, shares soar

Reuters
·
11 Dec 2024

BUZZ-Candel surges as prostate cancer therapy meets main goal of late-stage study

Reuters
·
11 Dec 2024

Candel Therapeutics' cancer drug meets late-stage trial goals

Reuters
·
11 Dec 2024

Candel Therapeutics Shares up 80.3% Premarket After Co's Prostate Cancer Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics -Safety Profile of Can-2409 Was Generally Consistent With Previous Studies, With No New Safety Signals Identified

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics Announces Can-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics Inc - Can-2409 Safety Profile Consistent With Previous Studies

THOMSON REUTERS
·
11 Dec 2024

Candel Therapeutics Inc - to Initiate FDA Discussions for Can-2409 Approval

THOMSON REUTERS
·
11 Dec 2024